PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers
Status:
Completed
Trial end date:
2015-04-20
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo controlled, two period crossover study to investigate the
pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in
healthy young versus elderly male and female subjects. Treatment periods will be separated by
13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.